Get the Stockscreener App
20.80
1.12%
0.19
Denali Therapeutics Inc stock is traded at $20.80, with a volume of 558.67K.
It is up +1.12% in the last 24 hours and up +23.53% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$20.61
Open:
$20.64
24h Volume:
558.67K
Relative Volume:
0.36
Market Cap:
$3.25B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-7.2982
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
+18.88%
1M Performance:
+23.53%
6M Performance:
+52.45%
1Y Performance:
-10.13%
1-Day Range:
$20.36
$21.12
1-Week Range:
$17.52
$21.39
52-Week Range:
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.80 | 3.22B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.56 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.75 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
867.30 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.98 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.10 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Short Covering: What are the future prospects of Lotterycom IncInsider Selling & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Denali Therapeutics Inc. $DNLI Shares Sold by Baillie Gifford & Co. - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3%Here's Why - MarketBeat
Shorts Report: What are analysts price targets for Denali Therapeutics IncExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
3 Biotech Stocks That Could Double In 2026 - AOL.com
Stock Market Recap: What are analysts price targets for Denali Therapeutics IncJuly 2025 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Liquidity Mapping Around (DNLI) Price Events - Stock Traders Daily
Aug Big Picture: Can Denali Therapeutics Inc withstand a market correctionRate Hike & Daily Volume Surge Signals - baoquankhu1.vn
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aug Breakouts: Whats the outlook for Denali Therapeutics Incs sectorPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug Chart Watch: Whats the outlook for Denali Therapeutics Incs sectorAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 40% Undervalued - 富途牛牛
Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Aug Patterns: Can Denali Therapeutics Inc withstand a market correctionMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
FOMO Trade: What makes FTRE stock attractive todayInflation Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress - Investing.com
Earnings Recap: Is BranchOut Food Inc a strong growth stockAnalyst Upgrade & AI Powered Market Trend Analysis - baoquankhu1.vn
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - 富途资讯
Bear Alert: Will Denali Therapeutics Inc benefit from government policy2025 Market Overview & Fast Entry High Yield Stock Tips - baoquankhu1.vn
DNLI: Imminent approval and strong clinical progress drive growth for transferrin receptor-enabled therapies - TradingView — Track All Markets
Denali Therapeutics unveils portfolio goals for 2026, stock up - MSN
Market Outlook: Is Denali Therapeutics Inc a turnaround storyStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring An 83% Upside Potential - DirectorsTalk Interviews
Rate Hike: Can Denali Therapeutics Inc scale operations efficientlyQuarterly Investment Review & Stepwise Trade Signal Implementation - baoquankhu1.vn
Have Denali Therapeutics Insiders Been Selling Stock? - simplywall.st
Why (DNLI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Denali Therapeutics Advances in MPS II Treatment: A Study Update - MSN
Is Denali Therapeutics Inc. stock a good choice for value investors2025 Technical Patterns & Daily Volume Surge Trade Alerts - ulpravda.ru
What insider trading reveals about Denali Therapeutics Inc. stockRecession Risk & AI Powered Market Trend Analysis - Улправда
Investment Recap: Is Denali Therapeutics Inc stock recession proof2025 Top Gainers & Precise Buy Zone Identification - moha.gov.vn
DNLI Stock Price, Forecast & Analysis | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - Chartmill
Why analysts upgrade Denali Therapeutics Inc. stockQuarterly Trade Report & Low Drawdown Momentum Trade Ideas - Улправда
What RSI levels show for Denali Therapeutics Inc. (4DN) stockJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - Улправда
Ryan Watts Sells 35,198 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Sells Shares - TradingView — Track All Markets
Is Denali Therapeutics Inc. stock recession proofJuly 2025 Final Week & AI Powered Buy and Sell Recommendations - Улправда
Will Denali Therapeutics Inc. stock reach all time highs in 2025Quarterly Market Summary & Long-Term Growth Plans - Улправда
What risks investors should watch in Denali Therapeutics Inc. stockStochastic Oscillator Alerts & Outstanding Profit Investment - Улправда
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $284,097.00 in Stock - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - Yahoo Finance
The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review - Yahoo Finance
Performance Recap: Will Denali Therapeutics Inc. stock reach all time highs in 20252025 EndofYear Setup & Risk Managed Investment Entry Signals - Bộ Nội Vụ
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up - sharewise.com
Will Denali Therapeutics Inc. stock see insider buyingMarket Depth Overview & Unlock Patterns Humans Can’t See - Улправда
Denali Therapeutics outlines key milestones for 2026 By Investing.com - Investing.com Nigeria
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential - Investing.com South Africa
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flows2026 world cup usa national team round of 32 young talents transition play winner prediction expert opinion - ulpravda.ru
Denali Prepares For Key Clinical And Regulatory Milestones - Nasdaq
Denali Therapeutics announces key anticipated milestones and priorities for 2026 - MarketScreener
Denali Therapeutics outlines key milestones for 2026 - Investing.com
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Denali Therapeutics Inc Stock (DNLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '26 |
Sale |
16.50 |
17,218 |
284,097 |
282,828 |
2.13%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):